SBL
GCVRZ

Sargent Bickham Lagudis’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Sargent Bickham Lagudis’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-600
Closed – – 845
2017
Q4 		$0 Hold
600
– – ﹤0.01% 884
2017
Q3 		$0 Hold
600
– – ﹤0.01% 864
2017
Q2 		$0 Hold
600
– – ﹤0.01% 848
2017
Q1 		$0 Hold
600
– – ﹤0.01% 805
2016
Q4 		$0 Hold
600
– – ﹤0.01% 785
2016
Q3 		$0 Hold
600
– – ﹤0.01% 828
2016
Q2 		$0 Hold
600
– – ﹤0.01% 802
2016
Q1 		$0 Buy
+600
New +$65 ﹤0.01% 746

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return

Sargent Bickham Lagudis's GCVRZ Position: Q1 2018 in Review

Sargent Bickham Lagudis sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2018, closing a stake of 600 shares.

Sargent Bickham Lagudis first reported a position in GCVRZ in Q1 2016 and held it in 8 quarters. The position peaked at $0 in Q4 2017. 100 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2018.

  • Sargent Bickham Lagudis reported no remaining Sanofi Contingent Value Rights position as of Q1 2018 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 600 Sanofi Contingent Value Rights shares in Q1 2018.
  • Sargent Bickham Lagudis first reported a position in Sanofi Contingent Value Rights in Q1 2016 and held it in 8 quarters.
  • Sargent Bickham Lagudis's Sanofi Contingent Value Rights position peaked at $0 in Q4 2017.
  • 100 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2018.

Based on Sargent Bickham Lagudis's 13F filing for Q1 2018, filed 13 Sep 2021.